U.K. Erectile Dysfunction Market - Industry Trends and Forecast to 2031

TABLE OF CONTENTS

1 INTRODUCTION 11

• 1.1 OBJECTIVES OF THE STUDY 11
• 1.2 MARKET DEFINITION 11
• 1.3 OVERVIEW OF U.K. ERECTILE DYSFUNCTION MARKET 11
• 1.4 CURRENCY AND PRICING 12
• 1.5 LIMITATIONS 12
• 1.6 MARKETS COVERED 13

2 MARKET SEGMENTATION 15

• 2.1 MARKETS COVERED 15
• 2.2 GEOGRAPHICAL SCOPE 16
• 2.3 YEARS CONSIDERED FOR THE STUDY 16
• 2.4 DBMR TRIPOD DATA VALIDATION MODEL 17
• 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
• 2.6 MULTIVARIATE MODELLING 21
• 2.7 MARKET END USER COVERAGE GRID 22
• 2.8 PRODUCT LIFELINE CURVE 23
• 2.9 DBMR MARKET POSITION GRID 24
• 2.10 VENDOR SHARE ANALYSIS 25
• 2.11 SECONDARY SOURCES 26
• 2.12 ASSUMPTIONS 26

3 EXECUTIVE SUMMARY 27

4 PREMIUM INSIGHTS 29

• 4.1 PESTEL ANALYSIS 30
• 4.2 PORTER'S FIVE FORCES MODEL 31
• 4.3 VENDOR SHARE ANALYSIS 32
• 4.4 BRAND ANALYSIS 33
  • 4.4.1 LEADING BRANDS 33
  • 4.4.2 BRAND POSITIONING 33
  • 4.4.3 MARKET PENETRATION 34
  • 4.4.4 COMPETITIVE ANALYSIS 35
• 4.5 CONSUMER INSIGHTS 36
  • 4.5.1 DEMOGRAPHIC INSIGHTS 36
  • 4.5.2 PSYCHOGRAPHIC PROFILE 36
  • 4.5.3 CONSUMER PREFERENCES 37
  • 4.5.4 PURCHASING BEHAVIOUR 37
  • 4.5.5 FACTORS INFLUENCING BUYING DECISION 37
• 4.6 PERFORMANCE ANALYSIS 39
  • 4.6.1 TREND ANALYSIS 39
• 4.7 RETAIL ANALYSIS 41

5 MARKET OVERVIEW 44

• 5.1 DRIVERS 46
  • 5.1.1 RISING PREVALENCE OF CHRONIC DISEASES 46
  • 5.1.2 RISING ADOPTION OF SEDENTARY LIFESTYLE AND ASSOCIATED STRESS 46
  • 5.1.3 RISING PRODUCT LAUNCHES BY MAJOR MARKET PLAYERS 47
  • 5.1.4 RISING PATIENT AWARENESS REGARDING THE CONDITION AND MEDICATION 47
• 5.2 RESTRAINTS 48
  • 5.2.1 REGULATORY CONSTRAINTS FOR APPROVAL 48
  • 5.2.2 HIGH COST OF ERECTILE DYSFUNCTION TREATMENT 48
• 5.3 OPPORTUNITIES 49
  • 5.3.1 AVAILABILITY OF PRESCRIPTION MEDICATION AND ITS GENERIC VERSION 49
  • 5.3.2 RISING TECHNOLOGICAL ADVANCEMENTS 49
  • 5.3.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 50
• 5.4 CHALLENGES 51
  • 5.4.1 VARIOUS SIDE EFFECTS ASSOCIATED WITH ERECTILE DYSFUNCTION DRUGS 51
  • 5.4.2 LACK OF SKILLED PROFESSIONALS 51

6 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE 52

• 6.1 OVERVIEW 53
• 6.2 DRUGS 56
  • 6.2.1 ORAL DRUGS 56
    • 6.2.1.1 BRANDED 57
      • 6.2.1.1.1 VIAGRA 57
      • 6.2.1.1.2 CIALIS 57
      • 6.2.1.1.3 LEVITRA 57
      • 6.2.1.1.4 AVANAFIL 57
      • 6.2.1.1.5 OTHERS 57
    • 6.2.1.2 GENERIC 57
  • 6.2.2 TOPICAL FORMULATION 58
  • 6.2.3 PENILE INJECTIONS 58
    • 6.2.3.1 PAPAVERINE 58
    • 6.2.3.2 PHENTOLAMINE 58
    • 6.2.3.3 PROSTAGLANDIN E1 (PGE1) 58
  • 6.2.4 SUPPOSITORIES 58
• 6.3 DEVICES 59
  • 6.3.1 PENIS PUMPS/VACCUM CONSTRICTION DEVICES 59
    • 6.3.1.1 HAND-POWERED 59
    • 6.3.1.2 BATTERY-POWERED PUMP 59
  • 6.3.2 PENILE IMPLANTS 60
    • 6.3.2.1 SEMIRIGID/MALLEABLE 60
    • 6.3.2.2 INFLATABLE 60
  • 6.3.3 SHOCK WAVE THERAPY 60

7 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE 61

• 7.1 OVERVIEW 62
• 7.2 SECONDARY ERECTILE DYSFUNCTION 65
• 7.3 PRIMARY ERECTILE DYSFUNCTION 65

8 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP 66

• 8.1 OVERVIEW 67
• 8.2 LESS THAN 40 70
• 8.3 40-60 70
• 8.4 60 AND ABOVE 70

9 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER 71

• 9.1 OVERVIEW 72
• 9.2 HOSPITALS 75
• 9.3 SPECIALTY CLINICS 75
• 9.4 HOME HEALTHCARE 75
• 9.5 AMBULATORY SURGICAL CENTERS 75
• 9.6 OTHERS 75

10 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL 76

• 10.1 OVERVIEW 77
• 10.2 DIRECT TENDERS 80
• 10.3 HOSPITAL PHARMACY 80
• 10.4 RETAIL PHARMACY 80
• 10.5 ONLINE PHARMACY 80
• 10.6 OTHERS 80

11 U.K. ERECTILE DYSFUNCTION MARKET, COMPANY LANDSCAPE 81

• 11.1 COMPANY SHARE ANALYSIS: GLOBAL 81

12 SWOT ANALYSIS 82

13 COMPANY PROFILES 83

• 13.1 PFIZER INC. 83
  • 13.1.1 COMPANY SNAPSHOT 83
  • 13.1.2 REVENUE ANALYSIS 83
  • 13.1.3 PRODUCT PORTFOLIO 84
  • 13.1.4 RECENT DEVELOPMENTS 84
• 13.2 LUPIN 85
  • 13.2.1 COMPANY SNAPSHOT 85
  • 13.2.2 REVENUE ANALYSIS 85
  • 13.2.3 PRODUCT PORTFOLIO 86
  • 13.2.4 RECENT DEVELOPMENTS 86
• 13.3 COLOPLAST CORP 87
  • 13.3.1 COMPANY SNAPSHOT 87
  • 13.3.2 REVENUE ANALYSIS 87
  • 13.3.3 PRODUCT PORTFOLIO 88
  • 13.3.4 RECENT DEVELOPMENTS 88
• 13.4 VIATRIS INC. 89
  • 13.4.1 COMPANY SNAPSHOT 89
  • 13.4.2 REVENUE ANALYSIS 89
  • 13.4.3 PRODUCT PORTFOLIO 90
  • 13.4.4 RECENT DEVELOPMENTS 90
• 13.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 91
  • 13.5.1 COMPANY SNAPSHOT 91
  • 13.5.2 REVENUE ANALYSIS 91
  • 13.5.3 PRODUCT PORTFOLIO 92
  • 13.5.4 RECENT DEVELOPMENTS 92
• 13.6 AUGUSTA MEDICAL SYSTEMS 93
  • 13.6.1 COMPANY SNAPSHOT 93
  • 13.6.2 PRODUCT PORTFOLIO 93
  • 13.6.3 RECENT DEVELOPMENT 93
• 13.7 BAYER AG 94
  • 13.7.1 COMPANY SNAPSHOT 94
  • 13.7.2 REVENUE ANALYSIS 94
  • 13.7.3 PRODUCT PORTFOLIO 95
  • 13.7.4 RECENT DEVELOPMENTS 95
• 13.8 BOSTON SCIENTIFIC CORPORATION 96
  • 13.8.1 COMPANY SNAPSHOT 96
  • 13.8.2 REVENUE ANALYSIS 96
  • 13.8.3 PRODUCT PORTFOLIO 97
  • 13.8.4 RECENT DEVELOPMENTS 97
• 13.9 ELI LILY AND COMPANY
  • 13.9.1 COMPANY SNAPSHOT 98
  • 13.9.2 REVENUE ANALYSIS 98
  • 13.9.3 PRODUCT PORTFOLIO 99
  • 13.9.4 RECENT DEVELOPMENTS 99
• 13.10 RIGICON, INC. 100
  • 13.10.1 COMPANY SNAPSHOT 100
  • 13.10.2 PRODUCT PORTFOLIO 100
  • 13.10.3 RECENT DEVELOPMENT 101
• 13.11 ZEPHYR SURGICAL IMPLANTS. 102
  • 13.11.1 COMPANY SNAPSHOT 102
  • 13.11.2 PRODUCT PORTFOLIO 102
  • 13.11.3 RECENT DEVELOPMENT 102

14 QUESTIONNAIRE 103

15 RELATED REPORTS 106

LIST OF TABLES

• TABLE 1 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 56
• TABLE 2 U.K. DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
• TABLE 3 U.K. ORAL DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
• TABLE 4 U.K. BRANDED IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 57
• TABLE 5 U.K. PENILE INJECTIONS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 58
• TABLE 6 U.K. DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 59
• TABLE 7 U.K. PENIS PUMPS/VACCUM CONSTRICTION DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 59
• TABLE 8 U.K. PENILE IMPLANTS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 60
• TABLE 9 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 65
• TABLE 10 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 70
• TABLE 11 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER, 2022-2031 (USD MILLION) 75
• TABLE 12 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 80

LIST OF FIGURES

• FIGURE 1 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION 15
• FIGURE 2 U.K. ERECTILE DYSFUNCTION MARKET: DATA TRIANGULATION 17
• FIGURE 3 U.K. ERECTILE DYSFUNCTION MARKET: DROC ANALYSIS 18
• FIGURE 4 U.K. ERECTILE DYSFUNCTION MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 19
• FIGURE 5 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY RESEARCH ANALYSIS 19
• FIGURE 6 U.K. ERECTILE DYSFUNCTION MARKET: INTERVIEW DEMOGRAPHICS 20
• FIGURE 7 U.K. ERECTILE DYSFUNCTION MARKET: MARKET END USER COVERAGE GRID 22
• FIGURE 8 U.K. ERECTILE DYSFUNCTION MARKET: DBMR MARKET POSITION GRID 24
• FIGURE 9 U.K. ERECTILE DYSFUNCTION MARKET: VENDOR SHARE ANALYSIS 25
• FIGURE 10 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION 28
• FIGURE 11 THE RISING RATES OF CHRONIC DISEASES AMONG MEN IS EXPECTED TO DRIVE THE GROWTH OF THE U.K. ERECTILE DYSFUNCTION MARKET FROM 2024 TO 2031 29
• FIGURE 12 THE DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.K. ERECTILE DYSFUNCTION MARKET IN 2024 AND 2031 29
• FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF U.K ERECTILE DYSFUNCTION MARKET 45
• FIGURE 14 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2022 53
• FIGURE 15 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION) 54
• FIGURE 16 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, CAGR (2024-2031) 54
• FIGURE 17 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, LIFELINE CURVE 55
• FIGURE 18 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2022 62
• FIGURE 19 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2024-2031 (USD MILLION) 63
• FIGURE 20 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, CAGR (2024-2031) 63
• FIGURE 21 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, LIFELINE CURVE 64
• FIGURE 22 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2022 67
• FIGURE 23 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2024-2031 (USD MILLION) 68
• FIGURE 24 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, CAGR (2024-2031) 68
• FIGURE 25 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, LIFELINE CURVE 69
• FIGURE 26 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2023 72
• FIGURE 27 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2024-2031 (USD MILLION) 73
• FIGURE 28 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, CAGR (2024-2031) 73
• FIGURE 29 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, LIFELINE CURVE 74
• FIGURE 30 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2022 77
• FIGURE 31 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 78
• FIGURE 32 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 78
• FIGURE 33 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 79
• FIGURE 34 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY SHARE 2023 (%) 81